We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Reasons to Invest in Essent Group (ESNT) Stock Right Now
Read MoreHide Full Article
It seems to be a wise idea to add Essent Group Ltd. (ESNT - Free Report) stock to your portfolio now, given the company’s strong fundamentals and solid earnings growth prospects. The company has been witnessing upward earnings estimate revisions, of late, indicating analysts’ optimism regarding its growth potential.
Moreover, the company’s price performance seems impressive. Its shares have appreciated 45.1% in the past six months compared with the industry’s rise of 24.4%. Given the upward estimate revisions and a solid Zacks Rank, the stock is expected to gain further.
Mentioned below are some other factors that make Essent Group an attractive pick right now.
Earnings per Share Growth: In the last three-five years, Essent Group witnessed earnings per share (EPS) growth of 42.9%, higher than the industry average of 13.6%. The uptrend is likely to continue in the near term, which can be seen from its projected earnings growth rate of 9.3% for 2019 as well as 2020.
The company’s long-term (three-five years) estimated EPS growth rate of 10% promises reward for shareholders.
Strong Leverage: Essent Group’s debt/equity ratio, which stands at 0.00, indicates that the company uses no debt to finance its operations. The industry’s debt/equity ratio stands at 0.66. This reflects the company’s financial stability, even amid adverse economic conditions.
Superior Return on Equity (ROE): Essent Group has an ROE of 21.36% compared with the industry average of 13.05%. This indicates that the company reinvests its cash more efficiently compared with its peers.
Valuation Looks Reasonable: Essent Group stock looks undervalued right now, with respect to its price-to-earnings (P/E) and PEG ratios. It has a P/E (F1) ratio of 9.14, lower than the industry average of 9.75. Additionally, the company’s PEG ratio of 0.91 is below the industry average of 1.45.
Further, Essent Group has a Value Score of B. Our research shows that stocks with a Value Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best upside potential.
Other Stocks Worth a Look
Some other top-ranked stocks from the finance space are Hilltop Holdings Inc. (HTH - Free Report) , Cadence Bancorporation (CADE - Free Report) and First Bancorp (FBNC - Free Report) . Each of these currently has a Zacks Rank of 2.
Over the past 60 days, Hilltop Holdings witnessed an upward earnings estimate revision of 11.5% for the current year. Its share price has increased 17.2% in the past six months.
Cadence Bancorporation’s Zacks Consensus Estimate for 2019 has been revised 8.8% upward over the past 60 days. Its shares have gained nearly 13.7% in the past six months.
Over the past 60 days, First Bancorp has witnessed an upward earnings estimate revision of 3% for the current year. Its share price has rallied 12.7% in the past six months.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
4 Reasons to Invest in Essent Group (ESNT) Stock Right Now
It seems to be a wise idea to add Essent Group Ltd. (ESNT - Free Report) stock to your portfolio now, given the company’s strong fundamentals and solid earnings growth prospects. The company has been witnessing upward earnings estimate revisions, of late, indicating analysts’ optimism regarding its growth potential.
.jpg)
The Zacks Consensus Estimate for its current-year earnings has been revised 1.5% upward over the past 60 days. Thus, the stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Moreover, the company’s price performance seems impressive. Its shares have appreciated 45.1% in the past six months compared with the industry’s rise of 24.4%. Given the upward estimate revisions and a solid Zacks Rank, the stock is expected to gain further.
Mentioned below are some other factors that make Essent Group an attractive pick right now.
Earnings per Share Growth: In the last three-five years, Essent Group witnessed earnings per share (EPS) growth of 42.9%, higher than the industry average of 13.6%. The uptrend is likely to continue in the near term, which can be seen from its projected earnings growth rate of 9.3% for 2019 as well as 2020.
The company’s long-term (three-five years) estimated EPS growth rate of 10% promises reward for shareholders.
Strong Leverage: Essent Group’s debt/equity ratio, which stands at 0.00, indicates that the company uses no debt to finance its operations. The industry’s debt/equity ratio stands at 0.66. This reflects the company’s financial stability, even amid adverse economic conditions.
Superior Return on Equity (ROE): Essent Group has an ROE of 21.36% compared with the industry average of 13.05%. This indicates that the company reinvests its cash more efficiently compared with its peers.
Valuation Looks Reasonable: Essent Group stock looks undervalued right now, with respect to its price-to-earnings (P/E) and PEG ratios. It has a P/E (F1) ratio of 9.14, lower than the industry average of 9.75. Additionally, the company’s PEG ratio of 0.91 is below the industry average of 1.45.
Further, Essent Group has a Value Score of B. Our research shows that stocks with a Value Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best upside potential.
Other Stocks Worth a Look
Some other top-ranked stocks from the finance space are Hilltop Holdings Inc. (HTH - Free Report) , Cadence Bancorporation (CADE - Free Report) and First Bancorp (FBNC - Free Report) . Each of these currently has a Zacks Rank of 2.
Over the past 60 days, Hilltop Holdings witnessed an upward earnings estimate revision of 11.5% for the current year. Its share price has increased 17.2% in the past six months.
Cadence Bancorporation’s Zacks Consensus Estimate for 2019 has been revised 8.8% upward over the past 60 days. Its shares have gained nearly 13.7% in the past six months.
Over the past 60 days, First Bancorp has witnessed an upward earnings estimate revision of 3% for the current year. Its share price has rallied 12.7% in the past six months.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>